康泰生物：三价流感病毒裂解疫苗获药物临床试验批准

Core Viewpoint - The company has received approval from the National Medical Products Administration for a trivalent influenza virus split vaccine developed in collaboration with Lanzhou Bailing Biotechnology Co., which is intended for individuals aged 3 and above [1] Group 1: Vaccine Development - The trivalent influenza vaccine is designed to stimulate the immune system to produce antibodies against influenza viruses, thereby preventing influenza caused by vaccine-related strains [1] - The company plans to initiate clinical trials for the vaccine as soon as possible [1] Group 2: Strategic Implications - Successful development of the vaccine will enhance the company's product portfolio, strengthening its core competitiveness and market position [1]